213 related articles for article (PubMed ID: 22110075)
1. Retinal venular caliber predicts visual outcome after intravitreal ranibizumab injection treatments for neovascular AMD.
Wickremasinghe SS; Busija L; Guymer RH; Wong TY; Qureshi S
Invest Ophthalmol Vis Sci; 2012 Jan; 53(1):37-41. PubMed ID: 22110075
[TBL] [Abstract][Full Text] [Related]
2. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
[TBL] [Abstract][Full Text] [Related]
3. Retinal venular calibre dilatation after intravitreal ranibizumab treatment for neovascular age-related macular degeneration.
Wickremasinghe SS; Guymer RH; Wong TY; Kawasaki R; Wong W; Qureshi S
Clin Exp Ophthalmol; 2012; 40(1):59-66. PubMed ID: 21668787
[TBL] [Abstract][Full Text] [Related]
4. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study).
Nguyen QD; Schachar RA; Nduaka CI; Sperling M; Klamerus KJ; Chi-Burris K; Yan E; Paggiarino DA; Rosenblatt I; Aitchison R; Erlich SS;
Ophthalmology; 2012 Sep; 119(9):1867-73. PubMed ID: 22683252
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
Saito M; Iida T; Kano M
Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
[TBL] [Abstract][Full Text] [Related]
7. Retinal blood flow in response to an intravitreal injection of ranibizumab for neovascular age-related macular degeneration.
Micieli JA; Tsui E; Lam WC; Brent MH; Devenyi RG; Hudson C
Acta Ophthalmol; 2012 Feb; 90(1):e13-20. PubMed ID: 21801339
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections.
Mekjavic PJ; Kraut A; Urbancic M; Lenassi E; Hawlina M
Acta Ophthalmol; 2011 Nov; 89(7):647-53. PubMed ID: 19860774
[TBL] [Abstract][Full Text] [Related]
9. Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study.
El-Mollayess GM; Mahfoud Z; Schakal AR; Salti HI; Jaafar D; Bashshur ZF
Am J Ophthalmol; 2012 Mar; 153(3):481-489.e1. PubMed ID: 22014603
[TBL] [Abstract][Full Text] [Related]
10. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab.
Cho HJ; Kim CG; Yoo SJ; Cho SW; Lee DW; Kim JW; Lee JH
Am J Ophthalmol; 2013 Jan; 155(1):118-126.e1. PubMed ID: 23022163
[TBL] [Abstract][Full Text] [Related]
11. Retinal vascular changes following intravitreal ranibizumab injections for neovascular AMD over a 1-year period.
Wickremasinghe SS; Xie J; Guymer RH; Wong TY; Kawasaki R; Qureshi S
Eye (Lond); 2012 Jul; 26(7):958-66. PubMed ID: 22562186
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of treatment efficacy of intravitreal ranibizumab injections in patients with wet type of AMD.
Lubiński W; Mozolewska-Piotrowska K; Krasodomska K; Penkala K; Kaźmierczak B; Karczewicz D
Klin Oczna; 2012; 114(3):187-93. PubMed ID: 23373399
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab for neovascular age-related macular degeneration in China.
Li X; Hu Y; Sun X; Zhang J; Zhang M;
Ophthalmology; 2012 Oct; 119(10):2087-93. PubMed ID: 22818896
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW
Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
[TBL] [Abstract][Full Text] [Related]
15. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration.
Mendrinos E; Mangioris G; Papadopoulou DN; Donati G; Pournaras CJ
Acta Ophthalmol; 2013 May; 91(3):e184-90. PubMed ID: 23590391
[TBL] [Abstract][Full Text] [Related]
17. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration.
Cunningham ET; Feiner L; Chung C; Tuomi L; Ehrlich JS
Ophthalmology; 2011 Dec; 118(12):2447-52. PubMed ID: 21872935
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
[TBL] [Abstract][Full Text] [Related]
19. The effect of fellow eye visual acuity on visual acuity of study eyes receiving ranibizumab for age-related macular degeneration.
Zweifel SA; Saroj N; Shapiro H; Freund KB
Retina; 2012 Jul; 32(7):1243-9. PubMed ID: 22466461
[TBL] [Abstract][Full Text] [Related]
20. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
